Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 46.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,658 shares of the company’s stock after purchasing an additional 4,348 shares during the period. EntryPoint Capital LLC’s holdings in Amphastar Pharmaceuticals were worth $507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMPH. Smartleaf Asset Management LLC lifted its stake in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after buying an additional 871 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares during the period. TD Private Client Wealth LLC grew its position in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares during the last quarter. Finally, KBC Group NV raised its stake in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after acquiring an additional 650 shares during the period. 65.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Piper Sandler cut their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $28.46 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $25.89 and a 1 year high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a fifty day moving average price of $31.72 and a two-hundred day moving average price of $40.36. The firm has a market cap of $1.36 billion, a P/E ratio of 9.49, a PEG ratio of 2.19 and a beta of 0.77.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.